Comparison · NCT02089737-sae
Panitumumab vs Concomitant Administration of Panitumumab and Chemotherapy: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Panitumumab vs Concomitant Administration of Panitumumab and Chemotherapy: serious adverse events. Trial comparisons, record NCT02089737-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02089737-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.49 | 0.462 | 0.517 | wilson | |
| Risk in group 2 | 0.408 | 0.386 | 0.431 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0817 | 0.0459 | 0.117 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.2 | 1.11 | 1.3 | log | |
| Odds ratio, group 1 over group 2 | 1.39 | 1.2 | 1.61 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Panitumumab than on Concomitant Administration of Panitumumab and Chemotherapy | 12.2 | 8.53 | 21.8 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Panitumumab | Panitumumab 6 mg/kg, intravenous drip infusion over a 60-minute period, once every 2 weeks for up to 42 weeks | 614 | 1,254 | EG000 |
| Group 2 | Concomitant Administration of Panitumumab and Chemotherapy | 747 | 1,831 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- For up to 42 weeks
Source ClinicalTrials.gov
Trial
- Title
Panitumumab for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveillance "Survey on Unresectable, Advanced or Recurrent Colorectal Cancer With Wild-type KRAS Gene" (All-patient Surveillance)
- NCT number
- NCT02089737
- Phases
- Conditions
- Advanced or Recurrent Colorectal Cancer
- Interventions
- Panitumumab
- Lead sponsor
- Takeda
- Results first posted
- 2017-04-06
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02089737?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02089737-sae